11745237

Source:http://linkedlifedata.com/resource/pubmed/id/11745237

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0042670, umls-concept:C0139121, umls-concept:C0205195, umls-concept:C0231491, umls-concept:C0242643, umls-concept:C0753474, umls-concept:C0920321
pubmed:issue	6
pubmed:dateCreated	2001-12-17
pubmed:abstractText	PSC 833 is a second-generation P-glycoprotein (Pgp) antagonist developed to reverse multidrug resistance (MDR). The authors conducted a Phase I study of orally administered PSC 833 in combination with vinblastine administered as a 5-day continuous infusion.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0374236
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporins, http://linkedlifedata.com/resource/pubmed/chemical/Emulsions, http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein, http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine, http://linkedlifedata.com/resource/pubmed/chemical/valspodar
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	0008-543X
pubmed:author	pubmed-author:BakkeSS, pubmed-author:BatesSS, pubmed-author:BerganRR, pubmed-author:ChenCC, pubmed-author:ChicoII, pubmed-author:ChoykePP, pubmed-author:CoteEE, pubmed-author:DhirD SDS, pubmed-author:GoldspielBB, pubmed-author:KangMM, pubmed-author:MeadowsBB, pubmed-author:MerinoMM, pubmed-author:RobelGG, pubmed-author:SmithTT
pubmed:copyrightInfo	Copyright 2001 American Cancer Society.
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	92
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1577-90
pubmed:dateRevised	2006-4-24
pubmed:meshHeading	pubmed-meshheading:11745237-Administration, Oral, pubmed-meshheading:11745237-Adolescent, pubmed-meshheading:11745237-Adrenal Cortex Neoplasms, pubmed-meshheading:11745237-Adult, pubmed-meshheading:11745237-Aged, pubmed-meshheading:11745237-Aged, 80 and over, pubmed-meshheading:11745237-Antineoplastic Agents, Phytogenic, pubmed-meshheading:11745237-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11745237-Carcinoma, Renal Cell, pubmed-meshheading:11745237-Cyclosporins, pubmed-meshheading:11745237-Drug Administration Schedule, pubmed-meshheading:11745237-Emulsions, pubmed-meshheading:11745237-Humans, pubmed-meshheading:11745237-Infusions, Intravenous, pubmed-meshheading:11745237-Kidney Neoplasms, pubmed-meshheading:11745237-Lymphocyte Count, pubmed-meshheading:11745237-Middle Aged, pubmed-meshheading:11745237-P-Glycoprotein, pubmed-meshheading:11745237-Radioimmunoassay, pubmed-meshheading:11745237-T-Lymphocytes, pubmed-meshheading:11745237-Vinblastine
pubmed:year	2001
pubmed:articleTitle	A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
pubmed:affiliation	Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. sebates@helix.nih.gov
pubmed:publicationType	Journal Article, Clinical Trial, Clinical Trial, Phase I